# NCT04246177 (NCT04246177)

> Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04246177
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Hepatocellular
- Interventions: Lenvatinib; Pembrolizumab; Oral Placebo; IV Placebo; TACE
- Enrollment: 480
- Primary outcome: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 61
- YouTube: 29
- Podcasts: 28
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04246177

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04246177", "email": "<work email>"}; the inbox owner confirms by the emailed link.